Sunshine Biopharma advances lead coronavirus drug candidate into IND-enabling studies
SBFM•Preclinical findings support further development
Studies showed broad activity across SARS-CoV-2 variants with favorable safety and drug-behavior findings in animals.
Animal testing indicated oral dosing reduced viral replication in the lungs, supporting the case for advancing development.
Lead coronavirus candidate moves into IND-enabling studies
Sunshine Biopharma moved its lead coronavirus drug candidate into IND-enabling studies on Sept. 16, 2026.
Preclinical results were previously presented in peer-reviewed publications in August 2024 and March 2026.
